| Open Trial |
Description |
| NCIC CTG OV.13 (Phase III) |
Who:Stage IIIC or IV epithelial ovarian, fallopian or peritoneal cancer (biopsy proven: no more surgery)
What:Study comparing upfront debulking vs neo-adjuvant chemotherapy in patients with stage IIIC or IV epithelial ovarian cancer |
| NCIC CTG OV.14 (Phase III) |
Who:Stage IIIC or IV epithelial ovarian, fallopian tube or peritoneal cancer (biopsy proven: no more surgery)
What:Study comparing paclitaxel/epirubicin/carboplatin (TEC) vs. paclitaxel/carboplatin (TC) in initial tx of pts with advanced ovarian cancer |
| OV-15 NCIC |
Who:In patients with advanced ovarian carcinoma who failed first line platinum-based therapy (protocol Ovar 2.5)
What:A Randomized Phase III Study comparing Gemcitabine Plus Carboplatin vs Carboplatin Monotherapy. |
| NESP-9980291 (Novel Erythropoiesis Stimulating Protein) |
Who:Treatment of anemia inpatients with solid tumors receiving multicycle chemotherapy.
What:Is a novel glycoprotein that stimulates erythropoiesis by the same mechanism as endogenous EPO subcutaneous injection of NESP once every 3 weeks (dosage determined by pt.'s wght) To be given on the same day of the week 3wks, and not to be delayed even if chemo is. |
